• Publications
  • Influence
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
TLDR
This chapter will review the mechanisms of action of heparin and LMWHs, their pharmacokinetics, anticoagulant effects, side effects, and laboratory monitoring, and the results of clinical trials will be discussed. Expand
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.
TLDR
Extrapolation of the data from this population-based study suggests that there are approximately 170,000 new cases of clinically recognized venous thromboembolism in patients treated in short-stay hospitals in the United States each year, and 99,000 hospitalizations for recurrent disease. Expand
Managing oral anticoagulant therapy.
TLDR
Evidence is reviews the evidence that indicates that an organized approach to anticoagulant management leads to better outcomes and focuses on dosing management and models of care. Expand
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
TLDR
The mainstay treatment for atrial fibrillation is Coumadin Aspirin Reinfarction, but the use of aspirin for other reasons is also being considered. Expand
Platelet-active drugs: the relationships among dose, effectiveness, and side effects.
TLDR
Abbreviations: ACE trial 5 Acetylsalicylic Acid and Carotid Endarterectomy; CAPRIE study 5 Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events; CI 5 confidence interval; COX 5 cyclooxygenase; DVT 5 deep venous thrombosis; EPISTENT trial 5 Evaluation of Platelet IIb/IIIa Inhibitors for Stenting. Expand
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th Edition). Grade 1Expand
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
TLDR
Abbreviations: ACT 5 activated clotting time; APTT 5 activated partial thromboplastin time; tPA 5 tissue plasminogen activator; UA 5 unstable angina; UFH 5 unfractionated heparin (CHEST 2001; 119:64S–94S). Expand
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1Expand
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
TLDR
The intensity of the therapeutic range has been lowered for mechanical prosthetic valves because of reports that a low intensity regimen is effective for this indication and because the risk of bleeding increases with increasing anticoagulant intensity. Expand
Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis.
TLDR
This work has shown that women with inherited clotting defects have a 9-fold to 19-fold increase in VTE if they use oral contraceptive agents and, if these speculations are correct, the detection of a hypercoagulable state could lead to a more focused approach to VTE prophylaxis. Expand
...
1
2
3
4
5
...